ASHP Paxlovid Resources

In July 2022, the Food and Drug Administration (FDA) revised its Emergency Use Authorization (EUA) to authorize pharmacists as prescribers of Paxlovid (Nirmatrelvir/Ritonavir) for the treatment of COVID-19. This resource page serves as a tool for pharmacists implementing Paxlovid prescribing in their practice. ASHP will continue to update this resource page as more information becomes available on implementation of this new prescribing privilege.

Resource Highlights